



(51) International Patent Classification:

C07D 513/08 (2006.01) A61P 35/00 (2006.01)

A61K 31/553 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/017505

(22) International Filing Date:

05 April 2023 (05.04.2023)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/327,656 05 April 2022 (05.04.2022) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).


(72) Inventors: REW, Yosup; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). LUU, Van; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). ZANCANELLA, Manuel; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). CHAVES, Mary; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: VOELKER, Alden, E. et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: AMORPHOUS AND CRYSTALLINE FORMS OF MCI-1 ANTAGONISTS



(AMG 176)

(57) Abstract: Disclosed herein are crystalline and amorphous forms of (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^{3,6}.0^{19,24}]pentacosane-15-one 13',13'-dioxide (AMG 176), and salts and hydrates thereof. Also disclosed are methods of making the crystalline and amorphous forms, and methods of treating diseases and disorders with the crystalline and amorphous forms.




AMORPHOUS AND CRYSTALLINE FORMS OF MCL-1 ANTAGONISTS**BACKGROUND****Technical Field**

[0001] The present disclosure relates to crystalline and amorphous forms of (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^{3,6}.0^{19,24}]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (AMG 176), hydrates, and salts thereof, which functions as an inhibitor of myeloid cell leukemia 1 protein (Mcl-1).

Description of Related Technology

[0002] The compound, (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^{3,6}.0^{19,24}]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (AMG 176), is useful as an inhibitor of myeloid cell leukemia 1 ("Mcl-1):




[0003] One common characteristic of human cancer is overexpression of Mcl-1. Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing the cells to survive despite widespread genetic damage.

[0004] Mcl-1 is a member of the Bcl-2 family of proteins. The Bcl-2 family includes pro-apoptotic members (such as BAX and BAK) which, upon activation, form a homo-oligomer in the outer mitochondrial membrane that leads to pore formation and the escape of mitochondrial contents, a step in triggering apoptosis. Antiapoptotic members of the Bcl-2 family (such as Bcl-2, Bcl-XL, and Mcl-1) block the activity of BAX and BAK. Other proteins (such as BID, BIM, BIK, and BAD) exhibit additional regulatory functions. Research has shown that Mcl-1 inhibitors can be useful for the treatment of cancers. Mcl-1 is overexpressed in numerous cancers.

[0005] U.S. Patent No. 9,562,061, which is incorporated herein by reference in its entirety, discloses AMG 176 as an Mcl-1 inhibitor and provides a method for preparing it. However, alternative forms of AMG 176 with improved properties are desirable, particularly for clinical use of AMG 176.

SUMMARY

[0006] Provided herein are crystalline and amorphous forms of AMG 176, wherein AMG 176 has the structure



[0007] Also provided are crystalline forms of AMG 176, characterized by solid state ¹³C NMR peaks at 12.39, 19.40, 20.46, 27.24, 28.07, 30.54, 33.09, 33.80, 37.18, 41.80, 42.98, 54.86, 58.69, 60.01, 63.11, 80.06, 85.77, 117.20, 119.77, 120.86, 127.04, 129.01, 129.71, 131.30, 132.24, 133.58, 139.16, 140.11, 140.69, 152.08, and 169.82 ± 0.5 ppm ("AMG 176 Form 1").

[0008] Also provided are crystalline forms of AMG 176 characterized by XRPD pattern peaks at 13.0, 16.9, and 17.3 ± 0.2° 2θ using Cu Kα radiation ("AMG 176 Form 2").

[0009] Also provided are amorphous forms of AMG 176, having an XRPD pattern substantially as shown in Figure 14 ("AMG 176 Amorphous").

[0010] Also provided are crystalline forms of AMG 176, as a calcium salt hydrate, characterized by XRPD pattern peaks at 6.8, 7.8, and 15.5 ± 0.2° 2θ using Cu Kα radiation ("AMG 176 Calcium Hydrate Form 1").

[0011] Also provided are crystalline forms of AMG 176, as a calcium salt hydrate, characterized by XRPD pattern peaks at 6.2, 20.2, and 24.4 ± 0.2° 2θ using Cu Kα radiation ("AMG 176 Calcium Hydrate Form 2").

[0012] Also provided are crystalline forms of AMG 176, as a calcium salt hydrate, characterized by XRPD pattern peaks at 6.2, 6.7, and 8.2 ± 0.2° 2θ using Cu Kα radiation ("AMG 176 Calcium Hydrate Form 3").

[0013] Also provided are amorphous forms of AMG 176, as a calcium salt hydrate, having an XRPD pattern substantially as shown in Figure 28 ("AMG 176 Amorphous Calcium Hydrate").

[0014] Also provided are pharmaceutical formulations comprising the crystalline or amorphous forms of AMG 176 as described herein and a pharmaceutically acceptable excipient.

[0015] Also provided are methods of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of the crystalline or amorphous forms of AMG 176 as described herein, or the pharmaceutical formulations comprising the crystalline or amorphous forms of AMG 176 as described herein and a pharmaceutically acceptable excipient.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] FIG. 1 depicts a solid state ¹³C NMR of the crystalline Form 1 of AMG 176.

- [0017] FIG. 2 depicts an X-ray powder diffraction ("XRPD") pattern of crystalline Form 1 of AMG 176.
- [0018] FIG. 3 depicts a differential scanning calorimetry ("DSC") thermograph of crystalline Form 1 of AMG 176.
- [0019] FIG. 4 depicts a thermogravimetric analysis ("TGA") trace of crystalline Form 1 of AMG 176.
- [0020] FIG. 5 depicts a moisture sorption profile (DVS) of crystalline Form 1 of AMG 176.
- [0021] FIG. 6 depicts a single crystal X-ray crystal structure of the unit cell of crystalline Form 1 of AMG 176.
- [0022] FIG. 7 depicts an overlay of X-ray powder diffraction ("XRPD") patterns of crystalline Form 1 of AMG 176 after solid state physical stability assessment. Form conversion was not observed after 8 weeks under stress conditions.
- [0023] FIG. 8 depicts an X-ray powder diffraction ("XRPD") pattern of the crystalline Form 2 of AMG 176.
- [0024] FIG. 9 depicts a differential scanning calorimetry ("DSC") thermograph of the crystalline Form 2 of AMG 176 indicating a onset and peak melting temperatures of approximately 233°C and 238°C, respectively.
- [0025] FIG. 10 depicts a differential scanning calorimetry ("DSC") thermograph and thermogravimetric analysis ("TGA") trace overlay of the crystalline 2-Me THF solvate Form 2 of AMG 176 showing a DSC onset at 176°C and 12.8% TGA weight loss between 140 – 215°C.
- [0026] FIG. 11 depicts a differential scanning calorimetry ("DSC") thermograph and thermogravimetric analysis ("TGA") trace overlay of the crystalline THF/water solvate Form 2 of AMG 176 showing a DSC onset at 177°C and 8.9% TGA weight loss between 140 – 200°C.
- [0027] FIG. 12 depicts a differential scanning calorimetry ("DSC") thermograph and thermogravimetric analysis ("TGA") trace overlay of the crystalline MTBE solvate Form 2 of AMG 176 showing a DSC onset at 163°C and 12.7% TGA weight loss between 140 – 190°C.
- [0028] FIG. 13 depicts a differential scanning calorimetry ("DSC") thermograph and thermogravimetric analysis ("TGA") trace overlay of the crystalline 1,4-dioxane/water solvate Form 2 of AMG 176 showing a DSC onset at 170°C and 10.1% TGA weight loss between 120 – 180°C.
- [0029] FIG. 14 depicts an X-ray powder diffraction ("XRPD") pattern of the amorphous form of AMG 176.
- [0030] FIG. 15 depicts a differential scanning calorimetry ("DSC") thermograph of the amorphous form of AMG 176 indicating a T_m of approximately 163°C.
- [0031] FIG. 16 depicts a thermogravimetric analysis ("TGA") trace of the amorphous form of AMG 176 showing 5.4% weight loss to 200°C, with 11.6% weight loss to 275°C.
- [0032] FIG. 17 depicts a thermogravimetric analysis ("TGA") trace of the amorphous form of AMG 176 showing

3.8% weight loss to 180°C.

[0033] FIG. 18 depicts a moisture sorption profile (DVS) of the amorphous form of AMG 176 showing weight gain of about 0.95 wt% water vapor between 5% and 95% relative humidity. More weight was lost upon desorption (1.59%) than was gained on adsorption, likely due to the loss of residual DCM and/or water from the starting material. XRPD of the post-DVS material was consistent with amorphous material.

[0034] FIG. 19 depicts an overlay of XRPD analysis of amorphous AMG 176 samples after solid state physical stability assessment. Crystallization not observed after 8 weeks under stress conditions.

[0035] FIG. 20 depicts an X-ray powder diffraction ("XRPD") pattern of the crystalline calcium salt hydrate Form 1 of AMG 176.

[0036] FIG. 21 depicts an overlaid differential scanning calorimetry ("DSC") thermograph and thermogravimetric analysis ("TGA") trace of the crystalline calcium salt hydrate Form 1 of AMG 176 indicating a melt at 301°C, recrystallization, and another melt at 322°C followed by degradation, and about 5.5% TGA weight loss.

[0037] FIG. 22 depicts an X-ray powder diffraction ("XRPD") pattern of the crystalline calcium salt hydrate Form 2 of AMG 176.

[0038] FIG. 23 depicts a moisture sorption profile (DVS) of the crystalline calcium salt hydrate Form 2 of AMG 176 showing weight gain of about 5.2% at 70% relative humidity and 23% weight gain at 95% relative humidity, which is likely due to the presence of residual NaCl.

[0039] FIG. 24 depicts an X-ray powder diffraction ("XRPD") pattern of the crystalline calcium salt hydrate form 3 of AMG 176.

[0040] FIG. 25 depicts a differential scanning calorimetry ("DSC") thermograph of the crystalline calcium salt hydrate form 3 of AMG 176 indicating a T_m of 314°C.

[0041] FIG. 26 depicts a thermogravimetric analysis ("TGA") trace of the crystalline calcium salt hydrate form 3 of AMG 176 showing 3.5% weight loss.

[0042] FIG. 27 depicts a moisture sorption profile (DVS) of the crystalline calcium salt hydrate form 3 of AMG 176 showing weight gain of about 7.4% of moisture at 95% relative humidity.

[0043] FIG. 28 depicts an X-ray powder diffraction ("XRPD") pattern of the amorphous calcium salt form of AMG 176.

[0044] FIG. 29 depicts an overlay of differential scanning calorimetry ("DSC") thermographs of forms of the calcium salt of AMG 176 (top to bottom: crystalline Form 2, amorphous form, and crystalline Form 1) indicating a T_m of 323°C, 295°C, and 322°C, respectively.


[0045] FIG. 30 depicts an overlay of thermogravimetric analysis ("TGA") traces of forms of the calcium salt of AMG 176 (top to bottom: amorphous form, crystalline Form 2, and crystalline Form 1) showing about 2.0% weight loss, about 3.1% weight loss, and about 5.5% weight loss, respectively.

[0046] FIG. 31 depicts a moisture sorption profile (DVS) of the amorphous calcium salt form of AMG 176 showing weight gain of about 9% to 95% relative humidity.

DETAILED DESCRIPTION

[0047] AMG 176 is a small molecule targeting the Mcl-1 pathway for the treatment of hematologic malignancies. High throughput (HTS) and manual screening experiments conducted to date were unsuccessful in isolating and/or scaling up an acceptable salt or cocrystal form for development. Polymorph screening on the free acid identified polymorphs disclosed herein, such as the crystalline free acid, AMG 176 Form 1, as a suitable form for development to support intravenous (IV) drug product development. AMG 176 polymorphs disclosed herein can also be amendable for oral delivery as an amorphous solid dispersion, if desired.

[0048] Disclosed herein are crystalline and amorphous forms of ((1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H,15'H-spiro[naphthalene-1,22'-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.0^{3,6}.0^{19,24}]pentacosa[8,16,18,24]tetraen]-15'-one 13',13'-dioxide (AMG



176), hydrates, and salts thereof:

(AMG 176). AMG 176 crystalline form 1 is

an anhydrous/non-solvated AMG 176 form and is likely thermodynamically stable between 2 and 79°C. AMG 176 crystalline form 1, can be advantageous over other, solvated forms due to improved properties for drug formulation.

[0049] Also provided herein are pharmaceutical formulations of crystalline and amorphous forms of AMG 176, and methods of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of a crystalline or amorphous form as disclosed herein.

[0050] U.S. Patent No. 9,562,061, which is incorporated by reference herein in its entirety, discloses synthetic procedures for synthesizing Mcl-1 inhibitors, such as AMG 176.

[0051] Further provided herein are crystalline hydrate forms of AMG 176, pharmaceutical formulations thereof, and methods of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of a crystalline hydrate form as disclosed herein.

[0052] The compounds disclosed herein may be identified either by their chemical structure and/or chemical name

herein. When the chemical structure and chemical name conflict, the chemical structure is determinative of the identity of the compound.

[0053] When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included.

[0054] As used herein, chemical structures which contain one or more stereocenters depicted with dashed and bold bonds (i.e.,  and ) are meant to indicate absolute stereochemistry of the stereocenter(s) present in the chemical structure. As used herein, bonds symbolized by a simple line do not indicate a stereo-preference. Unless otherwise indicated to the contrary, chemical structures that include one or more stereocenters which are illustrated herein without indicating absolute or relative stereochemistry encompass all possible stereoisomeric forms of the compound (e.g., diastereomers, enantiomers) and mixtures thereof. Structures with a single bold or dashed line, and at least one additional simple line, encompass a single enantiomeric series of all possible diastereomers.

[0055] The term "about" is meant to account for variations due to experimental error. All measurements reported herein are understood to be modified by the term "about," whether or not the term is explicitly used, unless explicitly stated otherwise. As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0056] "Treatment" or "treating" means any treatment of a disease in a patient, including: a) preventing the disease, that is, causing the clinical symptoms of the disease not to develop; b) inhibiting the disease; c) slowing or arresting the development of clinical symptoms; and/or d) relieving the disease, that is, causing the regression of clinical symptoms. Treatment of diseases and disorders herein is intended to also include the prophylactic administration of a pharmaceutical formulation described herein to a subject (i.e., an animal, preferably a mammal, most preferably a human) believed to be in need of treatment, such as, for example, cancer.

[0057] The term "therapeutically effective amount" means an amount effective, when administered to a human or non-human patient, to treat a disease, e.g., a therapeutically effective amount may be an amount sufficient to treat a disease or disorder responsive to inhibition of Mcl-1. The therapeutically effective amount may be ascertained experimentally, for example by assaying blood concentration of the chemical entity, or theoretically, by calculating bioavailability.

[0058] The term "solvate" refers to the chemical entity formed by the interaction of a solvate and a compound. Crystalline solvates of AMG 176 used in formulations herein are specifically contemplated. Solvents that can form crystalline solvate forms of AMG 176 include without limitation, 2-methyltetrahydrofuran (2-Me THF), tetrahydrofuran (THF), methyl tert-butyl ether (MTBE), 1,4-dioxane, water, and combinations thereof. In some cases, a solvate has 0.5 to 2 solvent molecules per AMG 176 molecule.

[0059] The term “hydrate” is a specific type of solvate, where the solvent is water. A hydrate, as used herein, can have a variable amount of water including, e.g., hemi-hydrates, monohydrates, dihydrates, trihydrates, etc. Crystalline hydrates of AMG 176 are specifically contemplated for use in the formulations disclosed herein. In some cases, the hydrate has 0.5 to 2 water molecules per AMG 176 molecule.

[0060] The term “polymorph” as used herein includes all crystalline and amorphous forms of the compound, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrides), and conformational polymorphs, as well as mixtures thereof, unless a particular crystalline or amorphous form is referred to. In some embodiments, the disclosure provides crystalline forms of AMG 176, for example, crystalline polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrides), and conformational polymorphs, as well as mixtures thereof, unless a particular crystalline form is referred to.

[0061] Crystalline Forms

[0062] Crystalline Form 1: The AMG 176 crystalline Form 1 can be characterized by solid state ^{13}C NMR, obtained as set forth in the Examples, having peaks at 12.39, 19.40, 20.46, 27.24, 28.07, 30.54, 33.09, 33.80, 37.18, 41.80, 42.98, 54.86, 58.69, 60.01, 63.11, 80.06, 85.77, 117.20, 119.77, 120.86, 127.04, 129.01, 129.71, 131.30, 132.24, 133.58, 139.16, 140.11, 140.69, 152.08, and 169.82 ± 0.5 ppm. In some embodiments, AMG 176 form 1 has a solid state ^{13}C NMR substantially as shown in Figure 1, wherein by “substantially” is meant that the reported peaks can vary by ± 0.5 ppm.

[0063] AMG 176 Form 1 can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, having peaks at 14.2, 18.0, and $18.6 \pm 0.2^\circ$ 2θ using Cu K α radiation, optionally further characterized by additional peaks at 12.6, 17.0, 22.7, and $26.6 \pm 0.2^\circ$ 2θ using Cu K α radiation, and/or additional peaks at 5.6, 12.3, 12.8, 14.5, 16.7, 24.4, 25.2, 27.1, 28.3, and $28.9 \pm 0.2^\circ$ 2θ using Cu K α radiation. In some embodiments, AMG 176 Form 1 has an X-ray powder diffraction pattern substantially as shown in Figure 2, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^\circ$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0064] Differential scanning calorimetry (DSC) thermographs were obtained, as set forth in the Examples, for AMG 176 Form 1. The DSC curve indicates an endothermic transition at $236^\circ\text{C} \pm 3^\circ\text{C}$. Thus, in some embodiments, the amorphous form of AMG 176 Form 1 can be characterized by a DSC thermograph having a transition endotherm with an onset of about 234°C . For example, in some embodiments AMG 176 Form 1 is characterized by DSC, as shown in Figure 3.

[0065] AMG 176 Form 1 can be characterized by thermogravimetric analysis (TGA). Thus, AMG 176 Form 1 can be characterized by a weight loss in a range of about 5.3% with an onset temperature of about 234°C. In some embodiments, AMG 176 Form 1 has a thermogravimetric analysis substantially as depicted in Figure 4, wherein by “substantially” is meant that the reported TGA features can vary by $\pm 5^\circ\text{C}$.

[0066] AMG 176 Form 1 can be characterized by a moisture sorption profile. For example, in some embodiments, AMG 176 Form 1 is characterized by the moisture sorption profile as shown in Figure 5, showing that AMG 176 Form 1 is non-hygroscopic up to 95% RH.

[0067] AMG 176 Form 1 can be characterized by a single crystal structure substantially as shown in Figure 6, or as set forth in the Examples.

[0068] Crystalline Form 2: AMG 176 crystalline Form 2 can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, having peaks at 13.0, 16.9, and $17.3 \pm 0.2^\circ 2\theta$ using Cu K α radiation, optionally further characterized by additional peaks at 19.1, 21.5, 22.7, 24.3, 27.0, 33.8, 40.0, and $42.8 \pm 0.2^\circ 2\theta$ using Cu K α radiation. In some embodiments, AMG 176 Form 2 has an X-ray powder diffraction pattern substantially as shown in Figure 8, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^\circ$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0069] Differential scanning calorimetry (DSC) thermographs were obtained, as set forth in the Examples, for AMG 176 Form 2. The DSC curve indicates an endothermic transition with an onset of 162°C to 169°C, 169°C to 173°C, 177°C to 179°C, 178°C to 182°C, or 232°C to 238°C. Thus, in some embodiments, AMG 176 Form 2 can be characterized by a DSC thermograph having a transition endotherm with an onset of about $163^\circ\text{C} \pm 3^\circ\text{C}$, $170^\circ\text{C} \pm 3^\circ\text{C}$, $176^\circ\text{C} \pm 3^\circ\text{C}$, $177^\circ\text{C} \pm 3^\circ\text{C}$, or $238^\circ\text{C} \pm 3^\circ\text{C}$. For example, in some embodiments AMG 176 Form 2 is characterized by DSC, as shown in Figure 9, Figure 10, Figure 11, Figure 12, or Figure 13. In some embodiments, the DSC curve indicates an endothermic transition with an onset of 232°C to 238°C, i.e., AMG 176 Form 2 can be characterized by a DSC thermograph having a transition endotherm with an onset of about $238^\circ\text{C} \pm 3^\circ\text{C}$. For example, in some embodiments AMG 176 Form 2 is characterized by DSC, as shown in Figure 9. In some embodiments, the DSC curve indicates an endothermic transition with an onset of 177°C to 179°C, i.e., AMG 176 Form 2 can be characterized by a DSC thermograph having a transition endotherm with an onset of about $176^\circ\text{C} \pm 3^\circ\text{C}$. For example, in some embodiments AMG 176 Form 2 is characterized by DSC, as shown in Figure 10. In some embodiments, the DSC curve indicates an endothermic transition with an onset of 178°C to 182°C, i.e., AMG 176 Form 2 can be characterized by a DSC thermograph having a transition endotherm with an onset of about $177^\circ\text{C} \pm 3^\circ\text{C}$. For example, in some embodiments AMG 176 Form 2 is characterized by DSC, as shown in Figure 11. In some embodiments, the DSC curve indicates an endothermic transition with an onset of 162°C to 169°C, i.e., AMG 176 Form 2 can be characterized by a DSC thermograph having a transition endotherm with an onset of about 163°C

$\pm 3^{\circ}\text{C}$. In some embodiments AMG 176 Form 2 is characterized by DSC, as shown in Figure 12. In some embodiments, the DSC curve indicates an endothermic transition with an onset of 169°C to 173°C , i.e., AMG 176 Form 2 can be characterized by a DSC thermograph having a transition endotherm with an onset of about $170^{\circ}\text{C} \pm 3^{\circ}\text{C}$. In some embodiments AMG 176 Form 2 is characterized by DSC, as shown in Figure 13.

[0070] AMG 176 Form 2 can be characterized by thermogravimetric analysis (TGA). Thus, AMG 176 Form 2 can be characterized by a weight loss in a range of about 12.8% between $140 - 215^{\circ}\text{C}$, about 8.9% between $140 - 200^{\circ}\text{C}$, about 12.7% between $140 - 190^{\circ}\text{C}$, or about 10.1% between $120 - 180^{\circ}\text{C}$. In some embodiments, AMG 176 Form 2 can be characterized by a weight loss in a range of about 12.8% between $140 - 215^{\circ}\text{C}$. In some embodiments, AMG 176 Form 2 can be characterized by a weight loss in a range of about about 8.9% between $140 - 200^{\circ}\text{C}$. In some embodiments, AMG 176 Form 2 can be characterized by a weight loss in a range of about about 12.7% between $140 - 190^{\circ}\text{C}$. In some embodiments, AMG 176 Form 2 can be characterized by a weight loss in a range of about 10.1% between $120 - 180^{\circ}\text{C}$. In some embodiments, AMG 176 Form 1 has a thermogravimetric analysis substantially as depicted in Figure 10, Figure 11, Figure 12, or Figure 13, wherein by “substantially” is meant that the reported TGA features can vary by $\pm 5^{\circ}\text{C}$. In some embodiments, AMG 176 Form 1 has a thermogravimetric analysis substantially as depicted in Figure 10. In some embodiments, AMG 176 Form 1 has a thermogravimetric analysis substantially as depicted in Figure 11. In some embodiments, AMG 176 Form 1 has a thermogravimetric analysis substantially as depicted in Figure 12. In some embodiments, AMG 176 Form 1 has a thermogravimetric analysis substantially as depicted in Figure 13.

[0071] Amorphous AMG 176 can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples. In some embodiments, amorphous AMG 176 has an X-ray powder diffraction pattern substantially as shown in Figure 14, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^{\circ}$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0072] Differential scanning calorimetry (DSC) thermographs were obtained, as set forth in the Examples, for amorphous AMG 176. The DSC curve indicates an endothermic transition at $122^{\circ}\text{C} \pm 3^{\circ}\text{C}$ or $163^{\circ}\text{C} \pm 3^{\circ}\text{C}$. In some embodiments, the DSC curve indicates an endothermic transition at $122^{\circ}\text{C} \pm 3^{\circ}\text{C}$. In some embodiments, the DSC curve indicates an endothermic transition at $163^{\circ}\text{C} \pm 3^{\circ}\text{C}$. Thus, in some embodiments, amorphous AMG 176 can be characterized by a DSC thermograph having a transition endotherm with an onset of 122°C to 130°C or 159°C to 166°C . In some embodiments, amorphous AMG 176 can be characterized by a DSC thermograph having a transition endotherm with an onset of 122°C to 130°C . In some embodiments, amorphous AMG 176 can be characterized by a DSC thermograph having a transition endotherm with an onset of 159°C to 166°C . For example, in some embodiments amorphous AMG 176 is characterized by DSC, as shown in Figure 15 or Figure 16. In some

embodiments amorphous AMG 176 is characterized by DSC as shown in Figure 15. In some embodiments amorphous AMG 176 is characterized by DSC as shown in Figure 16.

[0073] Amorphous AMG 176 can be characterized by thermogravimetric analysis (TGA). Thus, amorphous AMG 176 can be characterized by a weight loss of about 3.8 wt% between 28 and 180°C. In some embodiments, anhydrous AMG 176 has a thermogravimetric analysis substantially as depicted in Figure 17, wherein by “substantially” is meant that the reported TGA features can vary by $\pm 5^\circ\text{C}$.

[0074] Amorphous AMG 176 can be characterized by a moisture sorption profile. For example, in some embodiments, amorphous AMG 176 is characterized by the moisture sorption profile as shown in Figure 18, showing a weight gain of 0.95% by 95% RH.

[0075] AMG 176 Calcium Salt Hydrate Form 1 can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, having peaks at 6.8, 7.8, and $15.5 \pm 0.2^\circ 2\theta$ using Cu K α radiation, optionally further characterized by additional peaks at 11.6, 19.4, and $31.8 \pm 0.2^\circ 2\theta$ using Cu K α radiation. In some embodiments, AMG 176 Calcium Salt Hydrate Form 1 has an X-ray powder diffraction pattern substantially as shown in Figure 20, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^\circ$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0076] Differential scanning calorimetry (DSC) thermographs were obtained, as set forth in the Examples, for AMG 176 Calcium Salt Hydrate Form 1. The DSC curve indicates an endothermic transition at endothermic transitions at $301^\circ\text{C} \pm 3^\circ\text{C}$ and $322^\circ\text{C} \pm 3^\circ\text{C}$. Thus, in some embodiments, AMG 176 Calcium Salt Hydrate Form 1 can be characterized by a DSC thermograph having a transition endotherm with onsets of 298°C to 304°C and 319°C to 325°C . For example, in some embodiments AMG 176 Calcium Salt Hydrate Form 1 is characterized by DSC, as shown in Figure 21.

[0077] AMG 176 Calcium Salt Hydrate Form 1 can be characterized by thermogravimetric analysis (TGA). Thus, AMG 176 Calcium Salt Hydrate Form 1 can be characterized by a weight loss of about 5.5% weight loss that was confirmed to be due to the loss of water and ethanol by TGA-IR. In some embodiments, AMG 176 Calcium Salt Hydrate Form 1 has a thermogravimetric analysis substantially as depicted in Figure 21, wherein by “substantially” is meant that the reported TGA features can vary by $\pm 5^\circ\text{C}$.

[0078] AMG 176 Calcium Salt Hydrate Form 2 can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, having peaks at 6.2, 20.2, and $24.4 \pm 0.2^\circ 2\theta$ using Cu K α radiation, optionally further characterized by additional peaks at 15.5, 18.2, 19.3, and $21.6 \pm 0.2^\circ 2\theta$ using Cu K α radiation, and/or additional peaks at 10.8, 11.8, 13.9, 16.9, 17.5, 19.6, 22.7, 23.3, 23.5, 25.5, 26.0, and $26.5 \pm 0.2^\circ 2\theta$ using Cu K α radiation. In some embodiments, AMG 176 Calcium Salt Hydrate Form 2 has an X-ray powder diffraction pattern

substantially as shown in Figure 22, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^\circ$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0079] AMG 176 Calcium Salt Hydrate Form 2 can be characterized by a moisture sorption profile. For example, in some embodiments, AMG 176 Calcium Salt Hydrate Form 2 is characterized by the moisture sorption profile as shown in Figure 23, showing a weight gain of approximately 5.2% at 70% RH and 23% weight gain at 95% RH.

[0080] AMG 176 Calcium Salt Hydrate Form 3 can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, having peaks at 6.2, 6.7, and $8.2 \pm 0.2^\circ$ 2θ using Cu K α radiation, optionally further characterized by additional peaks at 17.4, 18.6, and $20.0 \pm 0.2^\circ$ 2θ using Cu K α radiation, and/or additional peaks at 11.1, 12.0, 13.0, 21.4, 25.4, and $29.4 \pm 0.2^\circ$ 2θ using Cu K α radiation. In some embodiments, AMG 176 Calcium Salt Hydrate Form 3 has an X-ray powder diffraction pattern substantially as shown in Figure 24, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^\circ$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0081] Differential scanning calorimetry (DSC) thermographs were obtained, as set forth in the Examples, for AMG 176 Calcium Salt Hydrate Form 3. The DSC curve indicates an endothermic transition at $314^\circ\text{C} \pm 3^\circ\text{C}$. Thus, in some embodiments, AMG 176 Calcium Salt Hydrate Form 3 can be characterized by a DSC thermograph having a transition endotherm with an onset of 311°C to 317°C . For example, in some embodiments AMG 176 Calcium Salt Hydrate Form 3 is characterized by DSC, as shown in Figure 25.

[0082] AMG 176 Calcium Salt Hydrate Form 3 can be characterized by thermogravimetric analysis (TGA). Thus, AMG 176 Calcium Salt Hydrate Form 3 can be characterized by a weight loss of about 3.5%. In some embodiments AMG 176 Calcium Salt Hydrate Form 3 has a thermogravimetric analysis substantially as depicted in Figure 26, wherein by “substantially” is meant that the reported TGA features can vary by $\pm 5^\circ\text{C}$.

[0083] AMG 176 Calcium Salt Hydrate Form 3 can be characterized by a moisture sorption profile. For example, in some embodiments, AMG 176 Calcium Salt Hydrate Form 3 is characterized by the moisture sorption profile as shown in Figure 27, showing a weight gain of 7.4% by 95% RH.

[0084] Amorphous AMG 176 Calcium Salt Hydrate can be characterized by an X-ray powder diffraction pattern, obtained as set forth in the Examples, substantially as shown in Figure 28, wherein by “substantially” is meant that the reported peaks can vary by $\pm 0.2^\circ$. It is well known in the field of XRPD that while relative peak heights in spectra are dependent on a number of factors, such as sample preparation and instrument geometry, peak positions are relatively insensitive to experimental details.

[0085] Differential scanning calorimetry (DSC) thermographs were obtained, as set forth in the Examples, for Amorphous AMG 176 Calcium Salt Hydrate. The DSC curve indicates an endothermic transition at $292^{\circ}\text{C} \pm 3^{\circ}\text{C}$. Thus, in some embodiments, Amorphous AMG 176 Calcium Salt Hydrate can be characterized by a DSC thermograph having a transition endotherm with an onset of 289°C to 295°C . For example, in some embodiments Amorphous AMG 176 Calcium Salt Hydrate is characterized by DSC, as shown in Figure 29.

[0086] Amorphous AMG 176 Calcium Salt Hydrate can be characterized by thermogravimetric analysis (TGA). Thus, Amorphous AMG 176 Calcium Salt Hydrate can be characterized by a weight loss in a range of about 2%. In some embodiments, Amorphous AMG 176 Calcium Salt Hydrate has a thermogravimetric analysis substantially as depicted in Figure 30, wherein by “substantially” is meant that the reported TGA features can vary by $\pm 5^{\circ}\text{C}$.

[0087] Amorphous AMG 176 Calcium Salt Hydrate can be characterized by a moisture sorption profile. For example, in some embodiments, Amorphous AMG 176 Calcium Salt Hydrate is characterized by the moisture sorption profile as shown in Figure 31, showing a weight gain of approximately 9% by 95% RH.

[0088] Pharmaceutical Formulations

[0089] Provided herein are pharmaceutical formulations comprising a crystalline form as disclosed herein and a pharmaceutically acceptable excipient.

[0090] In some embodiments, the pharmaceutical formulation is in the form of a tablet. In some embodiments, the pharmaceutical formulation is in the form of an immediate release tablet. Solid oral drug compositions (e.g., tablets) or preparations have various release profiles, such as an immediate release profile as referenced by FDA guidelines (“Dissolution Testing of Immediate Release Solid Oral Dosage Forms”, issued August 1997, Section IV-A). In the dissolution testing guideline for immediate release profiles, materials which dissolve at least 80% in the first 30 to 60 minutes in solution qualify as immediate release profiles. Therefore, immediate release solid dosage forms permit the release of most or all of the active ingredient over a short period of time, such as 60 minutes or less, and make rapid absorption of the drug possible. In contrast, extended release solid oral dosage forms permit the release of the active ingredient over an extended period of time in an effort to maintain therapeutically effective plasma levels over similarly extended time intervals, improve dosing compliance, and/or to modify other pharmacokinetic properties of the active ingredient.

[0091] “Pharmaceutically acceptable excipient” refers to a broad range of ingredients that may be combined with a compound or salt of the present invention to prepare a pharmaceutical composition or formulation. Excipients are additives that are included in a formulation because they either impart or enhance the stability, delivery and manufacturability of a drug product, and are physiologically innocuous to the recipient thereof. Regardless of the reason for their inclusion, excipients are an integral component of a drug product and therefore need to be safe and well tolerated by patients. Given the teachings and guidance provided herein, those skilled in the art will readily be

able to vary the amount or range of excipient without increasing viscosity to an undesirable level. Excipients may be chosen to achieve a desired bioavailability, desired stability, resistance to aggregation or degradation or precipitation, protection under conditions of freezing, lyophilization or high temperatures, or other properties. Typically, excipients include, but are not limited to, diluents, colorants, vehicles, anti-adherants, glidants, disintegrants, flavoring agents, coatings, binders, sweeteners, lubricants, sorbents, preservatives, and the like. Examples of suitable excipients are well known to the person skilled in the art of tablet formulation and may be found e.g. in *Handbook of Pharmaceutical Excipients* (eds. Rowe, Sheskey & Quinn), 6th edition 2009.

[0092] As used herein the term “excipients” is intended to refer to inter alia basifying agents, solubilizers, glidants, fillers, binders, lubricant, diluents, preservatives, surface active agents, dispersing agents and the like. The term also includes agents such as sweetening agents, flavoring agents, coloring agents and preserving agents. Such components will generally be present in admixture within the tablet.

[0093] Examples of solubilizers include, but are not limited to, ionic surfactants (including both ionic and non-ionic surfactants) such as sodium lauryl sulfate, cetyltrimethylammonium bromide, polysorbates (such as polysorbate 20 or 80), poloxamers (such as poloxamer 188 or 207), and macrogols.

[0094] Examples of lubricants, glidants and flow aids include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl behenate, sodium stearyl fumarate, colloidal silicon dioxide, and talc. The amount of lubricant in a tablet can generally be between 0.1-5% by weight.

[0095] Examples of disintegrants include, but are not limited to, starches, celluloses, cross-linked PVP, sodium starch glycolate, croscarmellose sodium, etc.

[0096] Examples of fillers (also known as bulking agents or diluents) include, but are not limited to, starches, maltodextrins, polyols (such as lactose), and celluloses. Tablets provided herein may include lactose and/or microcrystalline cellulose. Lactose can be used in anhydrous or hydrated form (e.g. monohydrate), and is typically prepared by spray drying, fluid bed granulation, or roller drying.

[0097] Examples of binders include, but are not limited to, cross-linked PVP, HPMC, microcrystalline cellulose, sucrose, starches, etc.

[0098] In some embodiments, the pharmaceutically acceptable excipients can comprise one or more diluent, binder, or disintegrant. In embodiments, the pharmaceutically acceptable excipients can comprise a diluent comprising one or more of microcrystalline cellulose, starch, dicalcium phosphate, lactose, sorbitol, mannitol, sucrose, and methyl dextrins, a binder comprising one or more of povidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and sodium carboxymethylcellulose, and a disintegrant comprising one or more of crospovidone, sodium starch glycolate, and croscarmellose sodium.

[0099] Tablets provided herein may be uncoated or coated (in which case they include a coating). Although uncoated tablets may be used, it is more usual to provide a coated tablet, in which case a conventional non-enteric coating may be used. Film coatings are known in the art and can be composed of hydrophilic polymer materials, but are not limited to, polysaccharide materials, such as hydroxypropylmethyl cellulose (HPMC), methylcellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), poly(vinylalcohol-co-ethylene glycol) and other water soluble polymers. Though the water soluble material included in the film coating of the present invention may include a single polymer material, it may also be formed using a mixture of more than one polymer. The coating may be white or colored e.g. gray. Suitable coatings include, but are not limited to, polymeric film coatings such as those comprising polyvinyl alcohol e.g. 'Opadry® II' (which includes part-hydrolysed PVA, titanium dioxide, macrogol 3350 and talc, with optional coloring such as iron oxide or indigo carmine or iron oxide yellow or FD&C yellow #6). The amount of coating will generally be between 2-4% of the core's weight, and in certain specific embodiments, 3%. Unless specifically stated otherwise, where the dosage form is coated, it is to be understood that a reference to % weight of the tablet means that of the total tablet, i.e. including the coating.

[00100] The pharmaceutical formulations disclosed herein can further comprise a surfactant. As used herein, the surfactant can be cationic, anionic, or non-ionic. In some embodiments, the pharmaceutical formulation can comprise a non-ionic surfactant. In some embodiments, the surfactant can comprise a polysorbate, a poloxamer, or a combination thereof. In some embodiments, the surfactant can comprise polysorbate 20, polysorbate 60, polysorbate 80, or a combination thereof.

[00101] Methods of Treating a Subject

[00102] Further provided herein are methods of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of an amorphous or crystalline form as disclosed herein, optionally as a pharmaceutical formulation as disclosed herein. In some embodiments, the cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia.

[00103] Preparation of Crystalline Forms

[00104] The crystalline forms disclosed herein can be prepared by a variety of methods known to those of skill in the art. For example, the crystalline forms can be prepared from amorphous, crude, or another crystalline form of AMG 176. In some embodiments, AMG 176 is combined with a solvent to form a desired crystalline form, for example as discussed in the examples below. In some embodiments, AMG 176 is dissolved in a solvent, or is combined with a solvent to form a slurry. In some embodiments, AMG 176 is combined with a solvent and the solution or slurry thus formed is aged to form the crystalline forms. In some embodiments, the solution or slurry is heated prior to aging or crystal formation.

Other Embodiments

[00105] It is to be understood that while the disclosure is read in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

EXAMPLES

[00106] The following examples are provided for illustration and are not intended to limit the scope of the invention.

Materials and Methods

[00107] Commercially available reagents are used as is without further purification unless specified.

[00108] The synthesis of the starting material (AMG 176) for the following methods is disclosed in U.S. Patent No. 9,562,061. The crystalline forms disclosed herein may be characterized using conventional means, including physical constants and spectral data.

[00109] **X-Ray Powder Diffraction:** X-ray powder diffraction data were obtained using a PANalytical X'Pert Pro diffractometer. The radiation used was CuK α (1.542 Å) with voltage and current of 45 kV and 40 mA. Data was collected at ambient temperature from 5.00 to 40.00° 2 θ using a step size of 0.0167°. A low background sample holder was used and the stage was rotated at a revolution time of 2.0 seconds. The incident beam path was equipped with a 0.02 rad soller slit, 15 mm mask, 4° fixed antiscatter slit and a programmable divergence slit. The diffracted beam was equipped with a 0.02 rad soller slit, programmable anti-scatter slit and a 0.02 mm nickel filter.

[00110] Alternatively, XRPD patterns were collected in transmission mode with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu radiation produced using an Optix long, fine-focus source. An elliptically graded multilayer mirror was used to focus Cu K α X-rays through the specimen and onto the detector. Prior to the analysis, a silicon specimen (NIST SRM 640e) was analyzed to verify the observed position of the Si 111 peak is consistent with the NIST-certified position. A specimen of the sample was sandwiched between 3- μ m-thick films and analyzed in transmission geometry. A beam-stop, short antiscatter extension and antiscatter knife edge were used to minimize the background generated by air. Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the specimen and Data Collector software v. 2.2b. The data acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) before the mirror.

[00111] XRPD patterns were collected in reflection mode with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu K α radiation produced using a long, fine-focus source and a nickel filter. The diffractometer

was configured using the symmetric Bragg-Brentano geometry. Prior to the analysis, a silicon specimen (NIST SRM 640e) was analyzed to verify the observed position of the Si 111 peak is consistent with the NIST-certified position. A specimen of the sample was packed in a well. Antiscatter slits (SS) were used to minimize the background generated by air. Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the sample and Data Collector software v. 2.2b. The data acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) and the incident-beam SS.

[00112] Within the figure referenced for a given indexed XRPD pattern, agreement between the allowed peak positions, marked with red bars, and the observed peaks indicates a consistent unit cell determination. Successful indexing of a pattern indicates that the sample is composed primarily of a single crystalline phase unless otherwise stated. Space groups consistent with the assigned extinction symbol, unit cell parameters, and derived quantities are tabulated below the figure. To confirm the tentative indexing solution, the molecular packing motifs within the crystallographic unit cells must be determined. No attempts at molecular packing were performed.

[00113] Single Crystal Structure: A colorless needle crystal (monohydrate) with dimensions 0.18 x 0.11 x 0.05 mm was mounted on a Nylon loop using very small amount of paratone oil. The crystal was mounted, cell determined to be the monohydrate, and then the temperature was raised to 400 °K to dehydrate. The crystal remained at 400 °K for 4 hours, and then lowered temperature to 173 °K and data collected. Data were collected using a Bruker CCD (charge coupled device) based diffractometer equipped with an Oxford Cryostream low-temperature apparatus operating at 173 °K. Data were measured using omega and phi scans of 0.5° per frame for 30 s. The total number of images was based on results from the program COSMO where redundancy was expected to be 4.0 and completeness to 100% out to 0.83 Å. Cell parameters were retrieved using APEX II software and refined using SAINT on all observed reflections. Data reduction was performed using the SAINT software. Scaling and absorption corrections were applied using SADABS multi-scan technique. The structures are solved by the direct method using the SHELXS-97 program and refined by least squares method on F², SHELXL-97, which are incorporated in SHELXTL-PC V 6.10.

[00114] Differential Scanning Calorimetry: Differential scanning calorimetry (DSC) analysis was conducted on a TA Instruments Q100 instrument. A sample size of approximately 1 mg was weighed out into a standard aluminum DSC pan; the pan was uncrimped. The sample was heated at 10°C/min from ambient temperature to 300°C under dry nitrogen at 50 mL/min. Modulated DSC analysis was conducted using a TA Instruments Q100 instrument. Sample sizes of approximately 1 mg were used in aluminum, uncrimped pan. The samples were equilibrated at 20°C and held for 5 minutes before heating to 300°C at a heating rate of 3°C/min under dry nitrogen at 50 mL/min. Modulation was ± 0.75°C every 45 seconds.

[00115] Alternatively, DSC was performed using a TA Instruments Q2000 differential scanning calorimeter.

Temperature calibration was performed using NIST-traceable indium metal. The sample was placed into an aluminum Tzero pan, covered with a lid, crimped, and the weight was accurately recorded. A weighed aluminum pan configured as the sample pan was placed on the reference side of the cell. The data acquisition parameters and pan configuration for each thermogram are displayed in the image in the Data section of this report. The method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., -30-250-10 means "from -30°C to 250°C, at 10°C/min".

[00116] Alternatively, MDSC data were obtained on a TA Instruments Q2000 differential scanning calorimeter equipped with a refrigerated cooling system (RCS). Temperature calibration was performed using NIST-traceable indium metal. The sample was placed into an aluminum DSC pan, and the weight was accurately recorded. The pan was covered with a lid and the lid was crimped. A weighed, crimped aluminum pan was placed on the reference side of the cell. Data were obtained using a modulation amplitude of $\pm 0.8^\circ\text{C}$ and a 60 second period with an underlying heating rate of $2^\circ\text{C}/\text{minute}$ from -30°C to 250°C. The reported glass transition temperature is obtained from the inflection point of the step change in the reversing heat flow versus temperature curve.

[00117] Alternatively, DSC was performed using a Mettler-Toledo DSC3+ differential scanning calorimeter. Temperature calibration was performed using adamantane, phenyl salicylate, indium, tin, and zinc. The sample was placed into a hermetically sealed or an open aluminum DSC pan, and the weight was accurately recorded. A weighed aluminum pan configured as the sample pan was placed on the reference side of the cell. The samples were analyzed from -30 to 250°C at a ramp rate of $10^\circ\text{C}/\text{min}$. Although thermograms are plotted by reference temperature (x-axis), results are reported according to sample temperatures.

[00118] **Thermal Analysis:** Thermogravimetric analysis was conducted on a TA Instruments Q500 instrument. A sample size of approximately 1-5 mg was used in an aluminum pan. The sample was heated at $10^\circ\text{C}/\text{min}$ from ambient temperature to 400°C under dry nitrogen at 25 mL/min.

[00119] Alternatively, TG analyses were performed using a TA Instruments Q5000 IR thermogravimetric analyzer. Temperature calibration was performed using nickel and Alumel™. Each sample was placed in an aluminum pan. The sample was hermetically sealed, the lid pierced, then inserted into the TG furnace. The furnace was heated under nitrogen. The data acquisition parameters for each thermogram are displayed in the image in the Data section of this report. The method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., 25-350-10 means "from 25°C to 350 °C, at $10^\circ\text{C}/\text{min}$ ".

[00120] Alternatively, Thermogravimetric analyses were performed using a Mettler Toledo TGA/DSC3+ analyzer. Temperature calibration was performed using phenyl salicylate, indium, tin, and zinc. The sample was placed in an aluminum pan. The open pan was inserted into the TG furnace. The furnace was heated under nitrogen. Each sample was heated from ambient temperature to 350°C at ramp rates of 2, 5, or $10^\circ\text{C}/\text{min}$. Although thermograms

are plotted by reference temperature (x-axis), results are reported according to sample temperatures.

[00121] Moisture Sorption: Moisture sorption data was collected at 25°C using a VTI vapor sorption analyzer. A sample size of approximately 4-10 mg was used in a standard platinum pan. Hygroscopicity was evaluated from 5 to 95% RH in increments of 5% RH. Data for adsorption and desorption cycles were collected. Equilibrium criteria were set at 0.001% weight change in 10 minute with a maximum equilibration time of 180 minutes.

[00122] NMR: Solution proton NMR spectra were acquired by Spectral Data Services of Champaign, IL at 25°C with a Varian UNITYINOVA-400 spectrometer. Samples were dissolved in DMSO-d₆. In some cases, the solution NMR spectra were acquired at SSCI with an Agilent DD2-400 spectrometer using deuterated DMSO or methanol.

[00123] ¹³C SSNMR data was collected on a Bruker DSX spectrometer operating at 600 MHz (¹H). A 4 mm H/F/X spinning probe operating at a spinning frequency of 14 kHz was used for all experiments. CPMAS with TOSS program was used with a recycle delay of 10 s. A ¹H 90° pulse of 2.5 μs and ¹³C 180° pulse of 8 μs were used. Decoupling was carried out using a spinal64 sequence. 4096 transients were acquired for signal averaging. The data was processed with Topspin 3.0 software.

Example 1: AMG 176 Form 1

[00124] AMG 176 Form 1 has acceptable pharmaceutical and physical properties, can be scaled to kilogram quantities, and can be compounded during drug product formulating as an in situ sodium salt to achieve desired drug concentrations to enable IV delivery. AMG 176 can also be converted to amorphous material to support oral dosing, if desired, depending on the dosing range. Dog PK studies suggested that absorption was improved by 10x when AMG 176 was dosed as an amorphous suspension as compared to the crystalline suspension. While improved exposures were observed by dosing the amorphous material, the exposures would likely plateau if gram level doses are needed for oral delivery.

[00125] AMG 176 (121 g) was dissolved in ethyl acetate. Ethanol (800 mL) was added, and the combination was mixed for 20 min while heating. Water (250 mL) was added dropwise over 30 min. The slurry was allowed to cool to room temperature for 2 h and then further cooled in an ice bath for 4 h prior to filtering. The wet cake was washed with cold 30% ethanol in water (300 mL). The cake was air dried for two days and then further dried under vacuum at 40°C for four days. Dried solids were identified as crystalline AMG 176 Form 1.

[00126] AMG 176 Form 1 consists of anhydrous/non-solvated AMG 176 and is likely thermodynamically stable between 2 and 79°C. An XRPD pattern for Form 1 was successfully indexed, indicating the material consists primarily or exclusively of a single crystalline phase. The unit cell volume obtained from the indexing solution contains minimal free volume, consistent with anhydrous/non-solvated AMG 176. A proton NMR spectrum for Form 1 was measured in deuterated DMSO. The spectrum was consistent with the chemical structure of AMG 176.

[00127] AMG 176 Form 1 was analyzed by DSC and TGA. Negligible weight loss is observed by TGA up to 220°C,

consistent with an anhydrous/non-solvated material (FIG. 4). The DSC thermogram is uneventful until the onset of a sharp endotherm at 232°C, likely corresponding with simultaneous melting and decomposition (FIG. 3).

[00128] AMG 176 Form 1 was also analyzed by DVS (FIG. 5). The material exhibited low hygroscopicity, taking up only 0.3% water vapor between 5% and 95% RH. All of this weight was lost upon desorption with virtually no hysteresis observed. XRPD of the post-DVS material indicated no form change (FIG. 7).

[00129] Table 1: XRPD Data Table

Pos. [°2Th.]	FWHM [°2Th.]	d-spacing [Å]	Height [cts]	Rel. Int. [%]
5.62	0.16	15.72	1159.12	16.00
8.35	0.19	10.58	155.73	2.15
12.30	0.16	7.20	1395.51	19.27
12.61	0.10	7.02	1932.24	26.68
12.81	0.10	6.91	1368.50	18.89
13.54	0.16	6.54	537.81	7.43
14.19	0.16	6.24	4709.46	65.02
14.50	0.10	6.11	1322.25	18.26
14.94	0.16	5.93	711.49	9.82
15.28	0.19	5.80	1042.99	14.40
16.69	0.19	5.31	1111.37	15.34
17.04	0.16	5.20	1883.03	26.00
17.98	0.26	4.93	7243.22	100.00
18.64	0.19	4.76	6735.32	92.99
19.05	0.13	4.66	1038.67	14.34
19.69	0.16	4.51	1028.18	14.20
21.05	0.29	4.22	197.66	2.73
22.11	0.16	4.02	960.66	13.26
22.72	0.16	3.91	1925.83	26.59
23.40	0.16	3.80	584.67	8.07
24.36	0.19	3.65	1468.17	20.27
25.21	0.23	3.53	1734.61	23.95
25.74	0.16	3.46	454.24	6.27
26.31	0.10	3.39	645.73	8.91
26.62	0.19	3.35	2615.20	36.11
27.10	0.19	3.29	1186.83	16.39
28.10	0.10	3.18	850.14	11.74
28.29	0.10	3.15	1107.43	15.29
28.86	0.13	3.09	1138.69	15.72
29.20	0.13	3.06	667.56	9.22
30.18	0.23	2.96	206.09	2.85
30.88	0.16	2.90	275.11	3.80

31.57	0.10	2.83	373.63	5.16
32.32	0.39	2.77	335.44	4.63
32.78	0.13	2.73	309.44	4.27
33.73	0.19	2.66	249.09	3.44
34.16	0.13	2.62	421.08	5.81
36.17	0.45	2.48	120.94	1.67
38.71	0.19	2.33	266.03	3.67
39.87	0.19	2.26	342.99	4.74
40.25	0.19	2.24	348.15	4.81
41.27	0.29	2.19	769.25	10.62
42.75	0.32	2.11	280.57	3.87

[00130] Single Crystal Data: The crystal structure of AMG 176 Form 1 was determined. The crystal parameters are summarized in Table 2 and the unit cell is displayed in FIG. 6.

[00131] Table 2: X-ray Single Structure Data

Crystal System	Orthorhombic
Space Group	P2 ₁ 2 ₁ 2 ₁
Unit Cell	a = 6.964 Å
	b = 14.402 Å
	c = 31.391 Å
	$\alpha = \beta = \gamma = 90^\circ$
Volume	3148 Å ³
Z	4
Density (calculated)	1.294 g/cm ³

[00132] Solid state stability assessment of AMG 176 Form 1 was conducted at 25°C/60% RH (open), 40°C (closed), 60°C (closed), and 40°C/75% RH (open) accelerated conditions to determine the chemical and physical stability of AMG 176. After 8 weeks, Form 1 was physically and chemically stable at all stress conditions, as displayed in FIG. 7.

Example 2: AMG 176 Form 2

[00133] AMG 176 Form 2 consists of an isostructural solvate containing 1 mole of 2-MeTHF, THF, MTBE, or 1,4-dioxane per mole of AMG 176. The form was produced from numerous slurry or vapor stress experiments in relevant solvent systems. A representative sample from each solvent was characterized by XRPD indexing, proton NMR, DSC, and TGA for comparison. The solvent systems that produced AMG 176 Form 2 were IPA/heptane, 2-MeTHF, THF/water, MTBE, and 1,4-dioxane/water.

[00134] Peak shifting was observed among the XRPD patterns, consistent with an isostructural solvate. The unit cell volume from the XRPD indexing solutions and the proton NMR spectra were all consistent with approximately 1 mole of the respective solvent in the crystal lattice. Additionally, the quantity of weight loss in each of the TGA

thermograms is consistent with the loss of between 0.8 and 1 mole of respective solvent. Desolvation events occur at slightly different onsets based on endotherms observed by DSC, and an overlay of DSC and TGA thermograms for each sample is presented in Figures 9-13 to illustrate differences in weight loss upon heating. The DSC thermograms for the samples from 2-MeTHF and 1,4-dioxane exhibit an exothermic event accompanying the desolvation endotherm, likely indicating form transformation.

[00135] Based on the DSC and TGA data, experiments were designed to explore the desolvation of various AMG 176 Form 2 samples by heating, vacuum, and VT-XRPD. Attempts to desolvate samples of Form 2 under vacuum at about 70°C and upon heating at about 164-165°C for 10 minutes were insufficient in removing the solvent.

[00136] An attempt to reproduce Form 2 by slurrying in 2-MeTHF at about 600 mg scale was successful. The material was utilized for form screen experiments.

[00137] For example, AMG 176 Form 2 was formed by slurrying AMG 176 in IPA/heptane (1:1, 8.4 mg/mL) at 25°C for 8 h. Solvent was allowed to evaporate. Remaining solids were identified as crystalline Form 2 by XRPD.

[00138] Table 3: XRPD Data Table

Pos. [°2Th.]	FWHM [°2Th.]	d-spacing [Å]	Height [cts]	Rel. Int. [%]
12.99	0.15	6.82	1415.50	59.05
16.90	0.15	5.25	2397.27	100.00
17.25	0.10	5.14	565.60	23.59
19.10	0.15	4.65	108.70	4.53
21.46	0.30	4.14	56.61	2.36
22.67	0.30	3.92	72.39	3.02
24.32	0.15	3.66	89.22	3.72
26.95	0.39	3.31	38.12	1.59
33.80	0.15	2.65	46.86	1.95
40.03	0.30	2.25	27.97	1.17
42.84	0.36	2.11	33.89	1.41

[00139] A summary of differentiating XRPD peaks between AMG Form 1 and Form 2 is presented in Table 4 below.

[00140] Table 4

Free Base Form	Peaks Unique to Each Form (KA1 °)					
Form 1	12.30	12.61	13.54	14.19	14.94	15.28
Form 2	12.99	17.25	21.46			

Example 3: Amorphous AMG 176

[00141] Amorphous material resulted from numerous evaporation and vapor diffusion experiments during a form screen. Noting the ease of preparation by fast evaporation, the material was prepared on a about 500 mg scale from DCM for use in additional form screen experiments and characterization.

[00142] The amorphous material was characterized by proton NMR, DVS, modulated DSC, and TGA. The proton NMR spectrum was consistent with the chemical structure of AMG 176.

[00143] The DVS isotherm is shown in Figure 18. The amorphous material exhibited limited hygroscopicity, taking up 0.95 wt% water vapor between 5% and 95% RH. More weight was lost upon desorption (1.59%) than was gained on adsorption, likely due to the loss of residual DCM and/or water from the starting material. XRPD of the post-DVS material was consistent with amorphous material.

[00144] The observation of a glass transition (T_g) can be characteristic of the non-crystalline nature of the material. Modulated DSC (mDSC) was performed to determine the T_g of the material and is shown in Figure 15. mDSC permits separation of the total heat flow signal into its thermodynamic (heat capacity) and kinetic components. Therefore, the T_g can typically be seen as a step change in the reversing signal. Amorphous AMG 176 exhibits a T_g at approximately 163°C (ΔC_p : 0.3 J/(g °C)). To be noted, differences in solvent and/or water content within the sample can shift the temperature at which the glass transition occurs.

[00145] A TGA thermogram is shown in Figure 17. Gradual weight loss of 3.8 wt% was observed between 28 and 180°C, consistent with the loss solvent (likely DCM and water).

[00146] Attempts to crystallize amorphous material were set up by vapor stressing and slurrying under various conditions. Most of the experiments caused crystallization to Form 1, with the exception of those that resulted in Form 2 from relevant solvent systems (1,4-dioxane/water, 2-MeTHF, and MTBE). Only one experiment, vapor stress with water at RT, did not cause crystallization, likely due to a lack of sufficient solubility.

[00147] For example, Amorphous AMG 176 was formed by dissolving AMG 176 (3.9 g) in a minimal amount of EtOAc then rapidly precipitating with heptane. The suspension was filtered. Remaining solids were identified as amorphous by XRPD.

[00148] Solid state stability assessment of AMG 176 amorphous material and Form 1 was conducted at 25°C/60% RH (open), 40°C (closed), 60°C (closed), and 40°C/75% RH (open) accelerated conditions to determine the chemical and physical stability of AMG 176. After 8 weeks, the amorphous material and Form 1 were physically and chemically stable at all stress conditions, as displayed in FIG. 19.

Example 4: AMG 176 Calcium Hydrate Form 1

[00149] AMG 176 sodium salt was dissolved in ethanol at 140 mg/mL to which 0.55eq $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ was added as a solution in ethanol resulting in a precipitate. The suspension was filtered and then a 0.5 mL aliquot of the filtrate was layered with heptane and then left at room temperature to crystallize. Solids were identified as crystalline by XRPD (Figure 20).

[00150] TGA analysis showed approximately 5.5% weight loss that was confirmed to be due to the loss of water and ethanol by TGA-IR. Approximately 0.5 molar equivalent of Ca was detected. The Ca salt appeared to melt at approximately 301°C, recrystallize, and undergo another melt at 322°C followed by degradation. The TGA and DSC data are presented in Figure 21.

[00151] Table 5: XRPD Data Table

Pos. [°2Th.]	FWHM [°2Th.]	d-spacing [Å]	Height [cts]	Rel. Int. [%]
6.77	0.16	13.06	7244.50	100
7.76	0.10	11.39	2682.06	37.02
11.64	0.13	7.60	822.86	11.36
15.54	0.10	5.70	2559.39	35.33
19.44	0.19	4.57	213.72	2.95
31.79	0.19	2.82	119.34	1.65

[00152] AMG 176 calcium hydrate Form 1 – ^1H NMR confirmed salt formation with residual ethanol. TGA analysis showed approximately 5.5% weight loss from 25-225°C that was confirmed to be due to the loss of water and ethanol by TGA-IR. Approximately 0.5 molar equivalent of Ca was detected by CE.

[00153] ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 0.78 - 1.04 (m, 4 H) 1.04 - 1.18 (m, 4 H) 1.18 - 1.29 (m, 1 H) 1.29 - 1.53 (m, 2 H) 1.54 - 1.79 (m, 4 H) 1.84 (br d, $J=7.67$ Hz, 3 H) 1.91 - 2.11 (m, 4 H) 2.22 - 2.49 (m, 3 H) 2.65 - 2.83 (m, 2 H) 2.89 - 3.07 (m, 1 H) 3.07 - 3.12 (m, 3 H) 3.17 (br d, $J=14.10$ Hz, 1 H) 3.34 - 3.60 (m, 6 H) 3.64 - 3.82 (m, 2 H) 3.82 - 4.06 (m, 5 H) 4.35 (t, $J=5.08$ Hz, 1 H) 5.36 (br dd, $J=15.45, 9.23$ Hz, 2 H) 6.00 (br s, 2 H) 6.73 (d, $J=8.09$ Hz, 2 H) 6.88 - 6.96 (m, 2 H) 7.01 (dd, $J=7.98, 1.76$ Hz, 2 H) 7.16 (d, $J=2.28$ Hz, 2 H) 7.27 (dd, $J=8.50, 2.28$ Hz, 2 H) 7.69 (d, $J=8.71$ Hz, 1 H).

Example 5: AMG 176 Calcium Hydrate Form 2

[00154] AMG 176 sodium was dissolved in EtOH at 43.6 mg/mL to which 0.55eq $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ was added as a solution in ethanol. To the filtrate seeds of AMG 176 calcium Form 1 were added then stirred at room temperature. Solids were identified as crystalline by XRPD (Figure 22).

[00155] AMG 176 Ca salt Form 2 has a weight loss of approximately 3.6% by TGA (Figure 30), consistent with 3.2% presence of water. Moisture sorption analysis showed a weight gain of approximately 5.2% at 70% RH and

23% weight gain at 95% RH, which is likely due to the presence of residual NaCl (Figure 23). The Ca content was determined to be 3.17%, which corresponds to approximately 0.5 mole of Ca. Aqueous solubility of this crystalline salt was determined to be approximately 24 µg/mL.

[00156] Table 6: XRPD Data Table

Pos. [°2Th.]	FWHM [°2Th.]	d-spacing [Å]	Height [cts]	Rel. Int. [%]
6.18	0.16	14.31	6355.17	100.00
7.85	0.16	11.27	1083.73	17.05
8.30	0.16	10.65	660.95	10.40
9.73	0.19	9.09	397.92	6.26
10.11	0.19	8.75	726.66	11.43
10.83	0.26	8.17	2221.33	34.95
11.79	0.26	7.50	2055.65	32.35
13.08	0.23	6.77	515.29	8.11
13.93	0.26	6.36	2081.42	32.75
14.75	0.19	6.01	628.86	9.90
15.49	0.26	5.72	2516.87	39.60
16.42	0.19	5.40	1013.66	15.95
16.88	0.19	5.25	1923.11	30.26
17.51	0.23	5.06	2121.53	33.38
18.23	0.23	4.87	2842.52	44.73
19.29	0.32	4.60	3208.45	50.49
19.61	0.10	4.53	1955.58	30.77
20.19	0.26	4.40	4717.35	74.23
20.88	0.23	4.25	665.88	10.48
21.58	0.29	4.12	2527.73	39.77
22.71	0.26	3.92	1474.97	23.21
23.27	0.13	3.82	1745.80	27.47
23.47	0.13	3.79	1704.15	26.82
24.40	0.29	3.65	3880.12	61.05
25.53	0.23	3.49	2165.24	34.07
26.02	0.19	3.42	2218.48	34.91
26.46	0.32	3.37	1335.35	21.01
27.40	0.16	3.25	957.94	15.07
28.01	0.19	3.19	1047.73	16.49
28.90	0.26	3.09	871.40	13.71
29.96	0.29	2.98	1157.74	18.22
30.40	0.19	2.94	615.78	9.69
31.91	0.29	2.80	1232.90	19.40
33.14	0.26	2.70	478.62	7.53
33.81	0.26	2.65	408.33	6.43

34.60	0.23	2.59	153.05	2.41
35.30	0.26	2.54	308.42	4.85
35.93	0.39	2.50	275.99	4.34
39.46	0.45	2.28	262.55	4.13
40.08	0.19	2.25	70.29	1.11
40.92	0.32	2.21	479.29	7.54
42.36	0.26	2.13	293.35	4.62
42.97	0.32	2.10	419.54	6.60

[00157] AMG 176 calcium hydrate Form 2 – ¹H NMR confirmed salt formation with residual ethanol. A 3.6% weight loss was seen on TGA from 25-225 °C. This was confirmed to be water by KF (3.2%). The Ca content was determined to be 3.17% by capillary electrophoresis which corresponds to 0.5 mol calcium.

[00158] ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.85 (d, *J*=6.01 Hz, 3 H) 0.99 - 1.21 (m, 5 H) 1.24 - 1.44 (m, 1 H) 1.55 - 1.79 (m, 3 H) 1.84 (br d, *J*=7.46 Hz, 3 H) 1.91 - 2.09 (m, 4 H) 2.22 - 2.48 (m, 2 H) 2.65 - 2.83 (m, 2 H) 2.89 - 3.07 (m, 1 H) 3.09 (s, 2 H) 3.13 - 3.31 (m, 1 H) 3.34 - 3.60 (m, 4 H) 3.72 (br d, *J*=14.93 Hz, 1 H) 3.85 - 4.03 (m, 3 H) 4.35 (t, *J*=5.08 Hz, 1 H) 5.36 (dd, *J*=15.34, 9.12 Hz, 1 H) 6.01 (br dd, *J*=15.65, 8.40 Hz, 1 H) 6.72 (d, *J*=8.09 Hz, 1 H) 6.91 - 6.97 (m, 1 H) 7.01 (dd, *J*=7.98, 1.76 Hz, 2 H) 7.16 (d, *J*=2.28 Hz, 2 H) 7.27 (dd, *J*=8.50, 2.28 Hz, 2 H) 7.70 (d, *J*=8.71 Hz, 1 H).

Example 6: AMG 176 Calcium Hydrate Form 3

[00159] AMG 176 calcium salt Form 2 was slurried at 17.5 mg/mL in water for 24 h at 25°C. Solids were identified as crystalline by XRPD.

[00160] Approximately 3.5% weight is lost upon TGA analysis (Figure 26), which is likely due to the loss of water based on KF results, 4.3% water. A melting point of approximately 314°C was observed by DSC analysis (Figure 25). The material was determined to be hygroscopic absorbing approximately 7.4% of moisture at 95% RH (Figure 27). The amount of Ca present in the sample was approximately 1.8%, which was lower than expected.

[00161] Table 7: XRPD Data Table

Pos. [°2Th.]	FWHM [°2Th.]	d-spacing [Å]	Height [cts]	Rel. Int. [%]
6.21	0.13	14.23	774.30	89.01
6.70	0.19	13.19	869.87	100.00
8.22	0.13	10.76	689.30	79.24
11.13	0.16	7.95	256.33	29.47
12.00	0.26	7.38	185.10	21.28
12.98	0.19	6.82	127.26	14.63
17.38	0.19	5.10	307.15	35.31
18.58	0.13	4.78	635.95	73.11

20.01	0.19	4.44	347.79	39.98
21.39	0.26	4.15	228.08	26.22
25.36	0.19	3.51	186.26	21.41
29.43	0.19	3.03	183.70	21.12

[00162] AMG 176 calcium hydrate Form 3 – ¹H NMR spectrum confirms salt formation and no residual organic solvent. Water content was 4.3% by KF.

[00163] ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.85 (br d, *J*=6.01 Hz, 3 H) 1.13 (d, *J*=7.05 Hz, 3 H) 1.36 (br t, *J*=9.85 Hz, 1 H) 1.55 - 1.79 (m, 3 H) 1.84 (br d, *J*=7.46 Hz, 2 H) 1.92 - 2.03 (m, 3 H) 2.21 - 2.48 (m, 2 H) 2.65 - 2.83 (m, 2 H) 2.89 - 3.07 (m, 1 H) 3.09 (s, 2 H) 3.13 - 3.31 (m, 1 H) 3.44 - 3.62 (m, 2 H) 3.72 (br d, *J*=14.72 Hz, 2 H) 3.86 - 4.06 (m, 3 H) 5.36 (br dd, *J*=15.24, 9.02 Hz, 2 H) 6.01 (br dd, *J*=15.13, 8.09 Hz, 1 H) 6.72 (d, *J*=8.09 Hz, 1 H) 6.92 - 6.97 (m, 1 H) 7.01 (dd, *J*=8.09, 1.66 Hz, 1 H) 7.16 (d, *J*=2.49 Hz, 1 H) 7.27 (dd, *J*=8.50, 2.49 Hz, 1 H) 7.70 (d, *J*=8.50 Hz, 1 H).

Example 7: Amorphous AMG 176 Calcium Hydrate

[00164] Amorphous AMG 176 Calcium Hydrate appeared as irregular shaped particles by microscopy with some minor presence of birefringence. When analyzed by XRPD, the amorphous material did not exhibit any characteristic diffraction peaks (Figure 28). Approximately 2% weight loss was observed by TGA (Figure 30), which is likely due to residual solvent. DSC analysis showed a melting endotherm at approximately 292°C (Figure 29). The amorphous material likely recrystallized during the analysis even though a clear recrystallization exotherm is not observed. Upon moisture sorption analysis, the amorphous material was determined to be hygroscopic gaining approximately 9% weight at 95% RH (Figure 31).

[00165] The amorphous material exhibited limited hygroscopicity, taking up 0.95 wt% water vapor between 5% and 95% RH. More weight was lost upon desorption (1.59%) than was gained on adsorption, likely due to the loss of residual DCM and/or water from the starting material. XRPD of the post-DVS material was consistent with amorphous material.

[00166] The foregoing description is given for clearness of understanding only, and no unnecessary limitations should be understood therefrom, as modifications within the scope of the invention may be apparent to those having ordinary skill in the art.

[00167] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise” and variations such as “comprises” and “comprising” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[00168] Throughout the specification, where compositions are described as including components or materials, it is

contemplated that the compositions can also consist essentially of, or consist of, any combination of the recited components or materials, unless described otherwise. Likewise, where methods are described as including particular steps, it is contemplated that the methods can also consist essentially of, or consist of, any combination of the recited steps, unless described otherwise. The invention illustratively disclosed herein suitably may be practiced in the absence of any element or step which is not specifically disclosed herein.

[00169] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

[00170] The practice of a method disclosed herein, and individual steps thereof, can be performed manually and/or with the aid of or automation provided by electronic equipment. Although processes have been described with reference to particular embodiments, a person of ordinary skill in the art will readily appreciate that other ways of performing the acts associated with the methods may be used. For example, the order of various of the steps may be changed without departing from the scope or spirit of the method, unless described otherwise. In addition, some of the individual steps can be combined, omitted, or further subdivided into additional steps.

[00171] The use of the terms "a," "an," "the," and similar referents in the context of the disclosure herein (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated. Recitation of ranges of values herein merely are intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended to better illustrate the disclosure herein and is not a limitation on the scope of the disclosure herein unless otherwise indicated. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure herein.

[00172] All patents, publications and references cited herein are hereby fully incorporated by reference. In case of conflict between the present disclosure and incorporated patents, publications and references, the present disclosure should control.

What is Claimed is:

1. A crystalline form of AMG 176, characterized by solid state ^{13}C NMR peaks at 12.39, 19.40, 20.46, 27.24, 28.07, 30.54, 33.09, 33.80, 37.18, 41.80, 42.98, 54.86, 58.69, 60.01, 63.11, 80.06, 85.77, 117.20, 119.77, 120.86, 127.04, 129.01, 129.71, 131.30, 132.24, 133.58, 139.16, 140.11, 140.69, 152.08, and 169.82 ± 0.5 ppm ("AMG 176 Form 1").
2. The crystalline form of claim 1, further characterized by XRPD pattern peaks at 14.2, 18.0, and $18.6 \pm 0.2^\circ$ 2θ using Cu K α radiation.
3. The crystalline form of claim 2, further characterized by XRPD pattern peaks at 12.6, 17.0, 22.7, and $26.6 \pm 0.2^\circ$ 2θ using Cu K α radiation.
4. The crystalline form of claim 3, further characterized by XRPD pattern peaks at 5.6, 12.3, 12.8, 14.5, 16.7, 24.4, 25.2, 27.1, 28.3, and $28.9 \pm 0.2^\circ$ 2θ using Cu K α radiation.
5. The crystalline form of any one of claims 1 to 4, having an XRPD pattern substantially as shown in Figure 2.
6. The crystalline form of any one of claims 1 to 5, having an endothermic transition at 233°C to 238°C , as measured by differential scanning calorimetry.
7. The crystalline form of claim 6, wherein the endothermic transition is at $236^\circ\text{C} \pm 3^\circ\text{C}$.
8. The crystalline form of any one of claims 1 to 7 having a thermogravimetric analysis ("TGA") substantially as shown in Figure 4.
9. A crystalline form of AMG 176 characterized by XRPD pattern peaks at 13.0, 16.9, and $17.3 \pm 0.2^\circ$ 2θ using Cu K α radiation ("AMG 176 Form 2").
10. The crystalline form of claim 9, further characterized by XRPD pattern peaks at 19.1, 21.5, 22.7, 24.3, 27.0, 33.8, 40.0, and $42.8 \pm 0.2^\circ$ 2θ using Cu K α radiation.
11. The crystalline form of claim 9 or 10, having an XRPD pattern substantially as shown in Figure 8.
12. The crystalline form of any one of claims 9 to 11, having an endothermic transition at 232°C to 238°C , as measured by differential scanning calorimetry.
13. The crystalline form of claim 12, wherein the endothermic transition is at $238^\circ\text{C} \pm 3^\circ\text{C}$.

14. The crystalline form of any one of claims 9 to 11, having an endothermic transition at 162°C to 169°C, 169°C to 173°C, 177°C to 179°C, or 178°C to 182°C, as measured by differential scanning calorimetry.
15. The crystalline form of claim 14, wherein the endothermic transition is at 163°C $\pm$ 3°C, 170°C $\pm$ 3°C, 176°C $\pm$ 3°C, or 177°C $\pm$ 3°C.
16. The crystalline form of any one of claims 9 to 15, having a thermogravimetric analysis ("TGA") substantially as shown in any one of Figures 10-13.
17. An amorphous form of AMG 176, having an XRPD pattern substantially as shown in Figure 14 ("AMG 176 Amorphous").
18. The amorphous form of claim 17, having an endothermic transition at 122°C to 130°C or 159°C to 166°C as measured by differential scanning calorimetry.
19. The amorphous form of claim 18, wherein the endothermic transition is at 122°C or 163°C $\pm$ 3°C.
20. The amorphous form of any one of claims 17 to 19, having a thermogravimetric analysis ("TGA") substantially as shown in Figure 17.
21. A crystalline form of AMG 176, as a calcium salt hydrate, characterized by XRPD pattern peaks at 6.8, 7.8, and 15.5 $\pm$ 0.2° 2 θ using Cu K α radiation ("AMG 176 Calcium Hydrate Form 1").
22. The crystalline form of claim 21, further characterized by XRPD pattern peaks at 11.6, 19.4, and 31.8 $\pm$ 0.2° 2 θ using Cu K α radiation.
23. The crystalline form of claim 21 or 22, having an XRPD pattern substantially as shown in Figure 20.
24. The crystalline form of any one of claims 21 to 23, having endothermic transitions at 301°C $\pm$ 3°C and 322°C $\pm$ 3°C, as measured by differential scanning calorimetry.
25. The crystalline form of any one of claims 21 to 24, having a thermogravimetric analysis ("TGA") substantially as shown in Figure 21.
26. A crystalline form of AMG 176, as a calcium salt hydrate, characterized by XRPD pattern peaks at 6.2, 20.2, and 24.4 $\pm$ 0.2° 2 θ using Cu K α radiation ("AMG 176 Calcium Hydrate Form 2").
27. The crystalline form of claim 26, further characterized by XRPD pattern peaks at 15.5, 18.2, 19.3, and 21.6 $\pm$ 0.2° 2 θ using Cu K α radiation.

28. The crystalline form of claim 26 or 27, further characterized by XRPD pattern peaks at 10.8, 11.8, 13.9, 16.9, 17.5, 19.6, 22.7, 23.3, 23.5, 25.5, 26.0, and $26.5 \pm 0.2^\circ$ 2θ using Cu K α radiation.
29. The crystalline form of any one of claims 26 to 28, having an XRPD pattern substantially as shown in Figure 22.
30. A crystalline form of AMG 176, as a calcium salt hydrate, characterized by XRPD pattern peaks at 6.2, 6.7, and $8.2 \pm 0.2^\circ$ 2θ using Cu K α radiation ("AMG 176 Calcium Hydrate Form 3").
31. The crystalline form of claim 30, further characterized by XRPD pattern peaks at 17.4, 18.6, and $20.0 \pm 0.2^\circ$ 2θ using Cu K α radiation.
32. The crystalline form of claim 30 or 31, further characterized by XRPD pattern peaks at 11.1, 12.0, 13.0, 21.4, 25.4, and $29.4 \pm 0.2^\circ$ 2θ using Cu K α radiation.
33. The crystalline form of any one of claims 30 to 32, having an XRPD pattern substantially as shown in Figure 24.
34. The crystalline form of any one of claims 30 to 33, having an endothermic transition at $314^\circ\text{C} \pm 3^\circ\text{C}$, as measured by differential scanning calorimetry.
35. The crystalline form of any one of claims 30 to 34, having a thermogravimetric analysis ("TGA") substantially as shown in Figure 26.
36. An amorphous form of AMG 176, as a calcium salt hydrate, having an XRPD pattern substantially as shown in Figure 28 ("AMG 176 Amorphous Calcium Hydrate").
37. The crystalline form of claim 36, having an endothermic transition at $292^\circ\text{C} \pm 3^\circ\text{C}$, as measured by differential scanning calorimetry.
38. The crystalline form of claim 36 or 37, having a thermogravimetric analysis ("TGA") substantially as shown in Figure 30.
39. A pharmaceutical formulation comprising the crystalline or amorphous form of any one of claims 1 to 38 and a pharmaceutically acceptable excipient.

40. A method of treating a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of the crystalline or amorphous form of any one of claims 1 to 38 or the pharmaceutical formulation of claim 39.
41. The method of claim 40, wherein the cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia.

1/25




FIG. 1




FIG. 2

3/25




FIG. 3




FIG. 4

SUBSTITUTE SHEET (RULE 26)

4/25




FIG. 5




FIG. 6

5/25





FIG. 7

6/25





FIG. 7
CONTINUED

7/25




FIG. 8

8/25




FIG. 9

9/25




FIG. 10

10/25




FIG. 11

11/25




FIG. 12

12/25




FIG. 13




FIG. 14

13/25




FIG. 15




FIG. 16

SUBSTITUTE SHEET (RULE 26)

14/25




FIG. 17




FIG. 18

----- 2944136#14_25C-60RH_open_1wk ----- 2944136#14_40C-75RH_open_4wk ----- 2944136#14_60C_closed_8wk
----- 2944136#14_25C-60RH_open_2wk ----- 2944136#14_40C-75RH_open_8wk_2 ----- 2944136#14_???-???-??? 1??
----- 2944136#14_25C-60RH_open_4wk ----- 2944136#14_60C_closed_1wk ----- 2944136#14_???-???-??? 2??
----- 2944136#14_25C-60RH_open_8wk_2 ----- 2944136#14_60C_closed_2wk ----- 2944136#14_???-???-??? 3??
----- 2944136#14_40C_closed_1wk ----- 2944136#14_60C_closed_4wk -----

Intensity (counts)
SUBSTITUTE SHEET (RULE 26)




FIG. 19




FIG. 20

18/25




FIG. 21




FIG. 22

19/25




FIG. 23




FIG. 24

SUBSTITUTE SHEET (RULE 26)

20/25




FIG. 25




FIG. 26

22/25




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31

© Surface Measurement Systems Ltd UK 1994

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2023/017505

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D513/08 A61K31/553 A61P35/00 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2016/033486 A1 (AMGEN INC [US]) 3 March 2016 (2016-03-03) cited in the application example 4	1-41
X,P	WO 2022/115400 A1 (AMGEN INC [US]) 2 June 2022 (2022-06-02) example 11	1-41
	----- -/--	
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
15 June 2023		26/06/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Bérillon, Laurent

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2023/017505

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP008166276, ISSN: 0340-1022, DOI: 10.1007/3-540-69178-2_5 [retrieved on 1999-02-26] the whole document -----	1-41

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2023/017505

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016033486 A1	03-03-2016	AR 101729 A1	11-01-2017
		AU 2015308735 A1	23-03-2017
		BR 112017004209 A2	31-07-2018
		CA 2959615 A1	03-03-2016
		CL 2017000469 A1	03-11-2017
		CN 107001387 A	01-08-2017
		CO 2017002998 A2	19-07-2017
		CR 20170116 A	28-04-2017
		CY 1121195 T1	29-05-2020
		DK 3186259 T3	25-02-2019
		EP 3186259 A1	05-07-2017
		EP 3424931 A2	09-01-2019
		ES 2706309 T3	28-03-2019
		ES 2777478 T3	05-08-2020
		HR P20190053 T1	22-02-2019
		HU E041806 T2	28-05-2019
		IL 257942 A	31-05-2018
		JO 3474 B1	05-07-2020
		JP 6502479 B2	17-04-2019
		JP 2017525730 A	07-09-2017
		KR 20170043661 A	21-04-2017
		LT 3186259 T	25-02-2019
		MA 40111 A1	29-06-2018
		ME 03313 B	20-10-2019
		NZ 729768 A	25-06-2021
		PE 20170892 A1	12-07-2017
		PH 12017500367 A1	10-07-2017
		PL 3186259 T3	30-04-2019
		PT 3186259 T	06-02-2019
		SG 11201701525W A	30-03-2017
		SI 3186259 T1	29-03-2019
		TN 2017000067 A1	04-07-2018
		TR 201901312 T4	21-02-2019
		TW 201625645 A	16-07-2016
		UA 118233 C2	10-12-2018
		US 2016068545 A1	10-03-2016
		US 2017088560 A1	30-03-2017
		US 2019016736 A1	17-01-2019
		US 2019023720 A1	24-01-2019
		US 2020062780 A1	27-02-2020
		US 2021040120 A1	11-02-2021
		UY 36285 A	01-04-2016
		WO 2016033486 A1	03-03-2016
		ZA 201701763 B	29-08-2018
		ZA 201802865 B	25-05-2022
WO 2022115400 A1	02-06-2022	AR 124282 A1	15-03-2023
		JP 2022084019 A	06-06-2022
		TW 202237557 A	01-10-2022
		UY 39538 A	31-05-2022
		WO 2022115400 A1	02-06-2022